These results suggest that, in contrast to its tumor-promoting role in the regulation of p53 activity, SIRT1 represses oncogenic estrogen signaling in breast cancer cells, both directly and indirectly, by deacetylating ERα and disrupting coactivator complex assembly. Here, TP53 is linked to neoplasm.